US Bancorp DE Sells 1,098 Shares of DaVita Inc. (NYSE:DVA)

US Bancorp DE lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 27.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,973 shares of the company’s stock after selling 1,098 shares during the quarter. US Bancorp DE’s holdings in DaVita were worth $445,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Quarry LP bought a new position in DaVita in the 3rd quarter worth approximately $60,000. Venturi Wealth Management LLC increased its stake in shares of DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after buying an additional 152 shares during the period. Versant Capital Management Inc increased its stake in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the period. Blue Trust Inc. boosted its position in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after purchasing an additional 131 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. bought a new stake in DaVita during the fourth quarter valued at about $82,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 2.8 %

DaVita stock opened at $142.57 on Thursday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50 day simple moving average of $159.28 and a 200-day simple moving average of $157.79. The stock has a market capitalization of $11.41 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 12 month low of $125.64 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.